WE ARE EXPLORING NEW OPTIONS FOR TREATMENT OF SLEEP DISORDERS
We focus our research and development efforts on modulation of GABA and NMDA receptors, two critical neurotransmitter systems that have responsibility for information flow within the intricate circuits of the brain and central nervous system. Both GABA and NMDA systems contribute significantly to regulating CNS function. However, dysfunction in these systems is known to be at the core of numerous disorders. Our novel compounds are designed to enhance the activity of the GABA or NMDA receptor systems, potentially helping to restore neurological balance important for many disorders.
Sleep disruption is a common issue associated with brain and CNS disorders. Many of the medicines currently used to treat insomnia target GABA receptors chemically. While effective, these medicines can have side-effects and tolerability issues that limit their use and benefit to patients. We are exploring whether one or more of the investigational medications we are developing may be able to offer a new option for the treatment of primary insomnia, as well as sleep disruptions associated with other conditions, such as major depressive disorder.